New developments in AMPK and mTORC1 cross-talk
Essays in Biochemistry · 18.11.2024 · 68 (3) · 321-336
DOI: 10.1042/ebc20240007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Essays in Biochemistry, online erschienen am 18.11.2024. Verfasst von William J Smiles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Signalling Laboratory, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, AMP-Activated Protein Kinases, Multiprotein Complexes. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC), Australian Research Council (ARC).
Abstract (Originalsprache)
Metabolic homeostasis and the ability to link energy supply to demand are essential requirements for all living cells to grow and proliferate. Key to metabolic homeostasis in all eukaryotes are AMPK and mTORC1, two kinases that sense nutrient levels and function as counteracting regulators of catabolism (AMPK) and anabolism (mTORC1) to control cell survival, growth and proliferation. Discoveries beginning in the early 2000s revealed that AMPK and mTORC1 communicate, or cross-talk, through direct and indirect phosphorylation events to regulate the activities of each other and their shared protein substrate ULK1, the master initiator of autophagy, thereby allowing cellular metabolism to rapidly adapt to energy and nutritional state. More recent reports describe divergent mechanisms of AMPK/mTORC1 cross-talk and the elaborate means by which AMPK and mTORC1 are activated at the lysosome. Here, we provide a comprehensive overview of current understanding in this exciting area and comment on new evidence showing mTORC1 feedback extends to the level of the AMPK isoform, which is particularly pertinent for some cancers where specific AMPK isoforms are implicated in disease pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Signalling Laboratory, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
- Research Program for Receptor Biochemistry and Tumour Metabolism, Department of Paediatrics, University Hospital of the Paracelsus Medical University, Salzburg, Austria.
- Protein Engineering in Immunity and Metabolism, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
- Protein Chemistry and Metabolism, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
- Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
- Mary Mackillop Institute for Health Research, Australian Catholic University, Fitzroy, Vic 3065, Vic. Australia.
ORCID-Profile: Jonathan S Oakhill
Förderung
- National Health and Medical Research Council (NHMRC)
- Australian Research Council (ARC)
Zitieren
APA
Smiles, W. J., Ovens, A. J., Kemp, B. E., Galic, S., Petersen, J., & Oakhill, J. S. (2024). New developments in AMPK and mTORC1 cross-talk. Essays in Biochemistry, 68(3), 321-336. https://doi.org/10.1042/ebc20240007
Vancouver
Smiles WJ, Ovens AJ, Kemp BE, Galic S, Petersen J, Oakhill JS. New developments in AMPK and mTORC1 cross-talk. Essays in Biochemistry. 2024;68(3):321-336. doi:10.1042/ebc20240007
BibTeX
@article{Smiles2024,
author = {Smiles, William J and Ovens, Ashley J and Kemp, Bruce E and Galic, Sandra and Petersen, Janni and Oakhill, Jonathan S},
title = {New developments in AMPK and mTORC1 cross-talk},
journal = {Essays in Biochemistry},
year = {2024},
volume = {68},
number = {3},
pages = {321--336},
doi = {10.1042/ebc20240007}
}
EUVIMED